Certain members of the thiazolidenedione family
Introduction
Thiazolidenediones, including troglitazone, rosiglitazone, pioglitazone, and ciglitazone, are synthetic ligands of the peroxisome proliferator-activated receptor g (PPARg; ref. 1) . This family of PPARg agonists improves insulin sensitivity by increasing transcription of certain insulin-sensitive genes involved in the metabolism and transport of lipids, thus representing a new class of p.o. antidiabetic agents. More recently, certain thiazolidenediones, especially troglitazone and ciglitazone, have also been shown to inhibit the proliferation of many cancer cell lines that express high levels of PPARg, including but not limited to those of colon, prostate, breast, and liposarcoma (2) . As PPARg-mediated effects of thiazolidenediones promote the differentiation of preadipocytes, one school of thought attributes the same mechanism to the terminal differentiation and cell cycle arrest of tumor cells (3) . However, the PPARg-activated target genes that mediate the antiproliferative effects remain elusive as genomic responses to PPARg activation in cancer cells are highly complicated (4) . Reported causal mechanisms include attenuated expression of protein phosphatase 2A (5) , cyclins D1 and E, inflammatory cytokines and transcription factors (2) , and increased expression of an array of gene products linked to growth regulation and cell maturation (4) . On the other hand, several lines of evidence indicate that the inhibitory effect of thiazolidenediones on tumor cell proliferation was independent of PPARg activation. For example, the antitumor effects seem to be structure specific, irrespective of potency in PPARg activation (i.e., troglitazone and ciglitazone are active, whereas rosiglitazone and pioglitazone are not). Also, there exists a 3-order-of-magnitude discrepancy between the concentration required to produce antitumor effects and that to mediate PPARg activation. To date, an array of non-PPARg targets have been implicated in the antitumor activities of troglitazone and/or ciglitazone in different cell systems, which include intracellular Ca 2+ stores (6) ; phosphorylating activation of extracellular signal-regulated kinases (7, 8) , c-Jun-NH 2 -kinase, and p38 (9) ; up-regulation of early growth response-1 (10), p27 kip1 (11) , p21 WAF/CIP1 (12) , p53, and Gadd45 (13) ; and altered expression of Bcl-2 family members (9) . However, some of these targets seem to be cell type-specific owing to differences in signaling pathways regulating cell growth and survival in different cell systems.
In light of the potential use of thiazolidenediones in prostate cancer prevention and treatment (14, 15) , signaling mechanisms whereby these PPARg agonists inhibit the proliferation of prostate cancer cells represent the focus of this investigation. We report here the development of novel thiazolidenedione derivatives that lack activity in PPARg activation but retain the ability to induce apoptosis in two prostate cancer cell lines with distinct PPARg expression status, suggesting that these two pharmacologic activities are unrelated. More importantly, we show that thiazolidenedione-mediated apoptosis was attributable in part to the inhibition of the anti-apoptotic functions of Bcl-xL and Bcl-2 by disrupting the BH3 domain-mediated interactions with proapoptotic Bcl-2 members. From a translational perspective, dissociation of these two pharmacologic activities (i.e., PPARg activation and Bcl-xL/Bcl-2 inhibition) provides a molecular basis to use 5-[4-(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-2,4-thiazolidine-dione (D2-TG) as a scaffold to generate a novel class of Bcl-xL/Bcl-2 inhibitors. Accordingly, we developed a structurally optimized D2-TG derivative (TG-88) with high in vivo potency in inhibiting PC-3 tumor growth.
Materials and Methods
Reagents. Troglitazone and ciglitazone were purchased from Sigma (St. Louis, MO) and Cayman Chemical (Ann Arbor, MI), respectively. Rosiglitazone and pioglitazone were prepared from the respective commercial capsules by solvent extraction followed by recrystallization or chromatographic purification. Fig. 1A) , and TG-88 are thiazolidenedione derivatives with attenuated or unappreciable activity in PPAR activation, of which the synthesis will be published elsewhere. The identity and purity (z99%) of these synthetic derivatives were verified by proton nuclear magnetic resonance, high-resolution mass spectrometry, and elemental analysis. For in vitro experiments, these agents at various concentrations were dissolved in DMSO, and were added to cells in medium with a final DMSO concentration of 0.1%. For the in vivo study, TG-88 was prepared as a suspension by sonication in a vehicle consisting of 0.5% methylcellulose and polysorbate 80 in sterile water. The pan-caspase inhibitor Z-VAD-FMK was purchased from BD Biosciences (Bedford, MA). The Cell Death Detection ELISA kit was purchased from Roche Diagnostics (Mannheim, Germany). The Nuclear Extract kit and PPARg Transcription Factor Assay kit were obtained from Active Motif (Carlsbad, CA). Rabbit antibodies against Bcl-xL, Bax, Bak, Bid, and cleaved caspase-9 were purchased from Cell Signaling Technology, Inc. (Beverly, MA). Rabbit antibodies against Bad, cytochrome c, and mouse anti-Bcl-2, anti-tubulin were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Mouse monoclonal anti-actin was from ICN Biomedicals, Inc. (Costa Mesa, CA). Goat anti-rabbit IgG-horseradish peroxidase conjugates and rabbit antimouse IgG horseradish peroxidase conjugates were from Jackson ImmunoResearch Laboratories (West Grove, PA). Hamster anti-human Bcl-2 antibody for immunoprecipitation was purchased from PharMingen (San Diego, CA).
Cell Culture. LNCaP androgen-dependent (p53
) and PC-3 androgennonresponsive (P53 À/À ) prostate cancer cells were obtained from the American Type Culture Collection (Manassas, VA), and were maintained in RPMI 1640 supplemented with 10% fetal bovine serum at 37jC in a humidified incubator containing 5% carbon dioxide. Preparation of the stable Bcl-xL-overexpressing LNCaP clones B11, B1, and B3 were previously described (16) .
Cell Viability Analysis. The effect of individual test agents on cell viability was assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in 6 to 12 replicates. Cells were seeded and incubated in 96-well, flat-bottomed plates in serum-free media for 24 hours and were exposed to various concentrations of test agents dissolved in DMSO ( final concentration, 0.1%) in serum-free RPMI 1640 for different time intervals. Controls received DMSO vehicle at a concentration equal to that in drug-treated cells. The medium was removed, replaced by 200 AL of 0.5 mg/mL MTT in 10% fetal bovine serum-containing RPMI 1640, and cells were incubated in the carbon dioxide incubator at 37jC for 2 hours. Supernatants were removed from the wells and the reduced MTT dye was solubilized in 200 AL/well DMSO. Absorbance at 570 nm was determined on a plate reader.
Apoptosis Detection by ELISA. Induction of apoptosis was assessed with a Cell Death Detection ELISA kit (Roche Diagnostics) following the manufacturer's instruction. This test is based on the quantitative determination of cytoplasmic histone-associated DNA fragments in the form of mononucleosomes and oligonucleosomes after induced apoptotic death. In brief, 1 Â 10 6 cells were cultured in a T-25 flask in 10% fetal bovine serum-containing medium for 24 hours, and were treated with the test agents at various concentrations in serum-free medium for 24 hours. Both floating and adherent cells were collected; cell lysates equivalent to 5 Â 10 5 cells were used in the ELISA.
Western Blot Analysis of Cytochrome c Release into the Cytoplasm. Cytosolic-specific, mitochondria-free lysates were prepared according to an established procedure (16) . In brief, after individual treatments for 24 . After a 45-minute incubation on ice, the mixture was centrifuged at 200 Â g for 10 minutes. The supernatant was collected in a microcentrifuge tube, and centrifuged at 14,000 rpm for 30 minutes. An equivalent amount of protein (50 Ag) from each supernatant was resolved in 10% SDS-polyacrylamide gel. Bands were transferred to nitrocellulose membranes and analyzed by immunoblotting with anti-cytochrome c antibodies as described below.
Immunoblotting. Cells in T-75 flasks were collected by scraping and suspended in 60 AL of PBS. Two microliters of the suspension was taken for protein analysis using the Bradford assay kit (Bio-Rad, Hercules, CA). The same volume of 2Â SDS-PAGE sample loading buffer [100 mmol/L Tris-HCl (pH 6.8), 4% SDS, 5% h-mercaptoethanol, 20% glycerol, and 0.1% bromophenol blue] was added to the remaining solution. The mixture was sonicated briefly and then boiled for 5 minutes. Equal amounts of proteins were loaded onto 10% SDS-PAGE gels.
After electrophoresis, protein bands were transferred to nitrocellulose membranes in a semidry transfer cell. The transblotted membrane was washed twice with TBS containing 0.1% Tween 20 (TBST). After blocking with TBST containing 5% nonfat milk for 40 minutes, the membrane was incubated with the appropriate primary antibody in TBST-1% nonfat milk at 4jC overnight. All primary antibodies were diluted 1:1,000 in 1% nonfat milk-containing TBST. After treatment with the primary antibody, the membrane was washed thrice with TBST for a total of 15 minutes followed by incubation with goat anti-rabbit or anti-mouse IgG-horseradish peroxidase conjugates (diluted 1:5,000) for 1 hour at room temperature and three washes with TBST for a total of 1 hour. The immunoblots were visualized by enhanced chemiluminescence.
Analysis of PPAR; Activation. The analysis was carried out by using a PPARg transcription factor ELISA kit (Active Motif) in which an oligonucleotide containing the peroxisome proliferator response element was immobilized onto a 96-well plate. PPARs contained in nuclear extracts bind specifically to this oligonucleotide and are detected through an antibody directed against PPARg. In brief, PC-3 cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum and treated with DMSO vehicle or individual test agents, 10 Amol/L each, for 48 hours. Cells were collected and nuclear extracts were prepared with a Nuclear Extract kit (Active Motif). Nuclear extracts of the same protein concentration from individual treatments were subject to the PPARg transcription factor ELISA according to the manufacturer's instruction.
Competitive Fluorescence Polarization Assay. The binding affinity of the test agent to Bcl-2 and Bcl-xL was analyzed by a competitive fluorescence polarization assay in which the ability of the agent to displace the binding of a Bak BH3-domain peptide to either Bcl-2 or Bcl-xL was determined. Flu-BakBH3, a Bak-BH3 peptide labeled at the NH 2 terminus with fluorescein, was purchased from Genemed Synthesis (San Francisco, CA). COOH-terminal-truncated, His-tagged Bcl-x L was purchased from EMD Biosciences (San Diego, CA) and soluble glutathione S-transferasefused Bcl-2 was obtained from Santa Cruz Biotechnology. The K D determination was carried out in a dual-path length quartz cell with readings taken at E em 480 nm and E ex 530 nm at room temperature using a luminescence spectrometer according to an established procedure (17) . Co-immunoprecipitation. PC3 cells treated with 50 Amol/L troglitazone or D2-TG for 12 hours were collected and lysed by NP40 isotonic lysis buffer with freshly added protease inhibitors [142 mmol/L KCl, 5 mmol/L MgCl 2 , 10 mmol/L HEPES (pH 7.2), 1 mmol/L EGTA, 0.2% NP40, 0.2 mmol/L phenylmethylsulfonyl fluoride, and 1 Ag/mL each aprotinin, leupeptin, and pepstatin]. After centrifugation at 13,000 Â g for 15 minutes, the supernatants were collected, preincubated with protein A-Sepharose (Sigma) for 15 minutes, and centrifuged at 1,000 Â g for 5 minutes. The supernatants were exposed to Bcl-2 or Bcl-xL antibodies in the presence of protein A-Sepharose at 4jC for 2 hours. After brief centrifugation, protein A-Sepharose were collected, washed with the aforementioned lysis buffer twice, suspended in 2Â SDS sample buffer, and subjected to Western blot analysis with antibodies against Bak.
Xenograft Tumor Growth. Male NCr athymic nude mice (5-7 weeks of age) were obtained from the National Cancer Institute (Frederick, MD). Mice were group-housed under conditions of a constant 12-hour photoperiod with ad libitum access to sterilized food and water. All experimental procedures utilizing these mice were done in accordance with protocols approved by the Institutional Laboratory Animal Care and Use Committee of the Ohio State University.
Each mouse was inoculated s.c. in the right flank with 5 Â 10 5 PC-3 cells suspended in 0.1 mL serum-free medium containing 30% Matrigel (BD Biosciences) under isoflurane anesthesia. Forty-eight hours later, mice were randomly divided into three groups (n = 8) and were given daily TG-88 at 100 and 200 mg/kg body weight per day by gavage for the duration of the study. Controls received vehicle consisting of 0.5% methylcellulose and 0.1% polysorbate 80 in sterile water. The volume of drug or vehicle administered to each mouse was 0.02 mL/g of body weight. Tumors were measured weekly using calipers and their volumes calculated using a standard formula: width 2 Â length Â 0.52. Body weights were measured weekly.
Statistical Analysis. For in vitro studies, data were analyzed by one-way ANOVA followed by Fisher's least significant difference method for multiple comparisons. These data are expressed as means F SD. For the in vivo study, tumor volume data failed to meet the assumption of normality (Shapiro-Wilk test) for parametric analysis; thus, group means were compared using Kruskall-Wallis ANOVA and Mann-Whitney U test. Tumor growth data are expressed as mean tumor volumes F SE. For all data, differences were considered significant at P < 0.05. Statistical procedures were done using SPSS for Windows (SPSS, Inc., Chicago, IL).
Results
Development of Thiazolidenedione Derivatives Lacking PPAR; Ligand Activity. It was reported that introduction of a double bond adjoining the terminal thiazolidine-2,4-dione ring of rosiglitazone abrogated its PPARg ligand property (19) . As part of our effort to discern the role of PPARg activation in the antitumor effects of thiazolidenediones, we synthesized this rosiglitazone derivative and the counterparts of troglitazone, pioglitazone, and ciglitazone, and examined the ability of the resulting molecules (D2-TG, D2-RG, D2-PG, and D2-CG) vis-à-vis their parent thiazolidenediones to activate PPARg in PC-3 cells (Fig. 1) .
Among these new compounds, D2-RG showed a 77% reduction in the activity in PPARg activation compared with rosiglitazone, which is in line with that reported in the literature (19) . In contrast, D2-TG, D2-PG, and D2-CG were completely devoid of the ligandbinding activity because the respective levels of PPARg activation were not statistically different from that of the DMSO vehicle (P < 0.01). The loss/attenuation of PPARg activity in these D2 derivatives was presumably attributable to the structural rigidity, as a result of the double bond introduction surrounding the heterocyclic system.
Apoptosis-Inducing Effects of Thiazolidenediones on Prostate Cancer Cells Are Independent of PPAR; Activation. We first assessed the dose-dependent growth inhibitory effect of troglitazone and D2-TG in two prostate cancer cell lines, androgenindependent PC-3 (p53 À/À ), and androgen-dependent LNCaP (p53 +/+ ). Among many genotypic differences, these two cell lines exhibit distinct PPARg expression status (i.e., PPARg was highly expressed in PC-3 cells but was deficient in LNCaP cells, P < 0.01; Fig. 2A; ref. 15) . Nevertheless, despite deficiency in PPARg, LNCaP cells exhibited a higher degree of susceptibility to troglitazonemediated in vitro antitumor effects compared with the PPARg-rich PC-3 cells (Fig. 2B) . In addition, D2-TG, although devoid of PPARgactivating activity, was more potent than troglitazone in suppressing cell proliferation in both cell lines. The respective IC 50 values for troglitazone and D2-TG were 30 F 2 and 20 F 2 Amol/L in PC-3 Figure 1 . Development of PPARg-inactive thiazolidenedione derivatives. A, chemical structures of troglitazone, rosiglitazone, pioglitazone, ciglitazone, and their respective D2 derivatives. B, D-2-thiazolidenedione derivatives lack activity in PPARg activation. Analysis of PPARg activation was carried out as described in Materials and Methods. In brief, PC-3 cells were exposed to individual test agents (10 Amol/L) or DMSO vehicle in 10% fetal bovine serum-supplemented RPMI 1640 for 48 hours. Amounts of activated PPARg in the resulting nuclear extracts were analyzed by PPARg transcription factor ELISA kit. Columns, mean; bars, SD (n = 3, *P < 0.01).
Troglitazone Induces Apoptosis in Prostate Cancer Cells www.aacrjournals.org cells, and 22 F 3 and 14 F 1 Amol/L in LNCaP cells. This growth inhibition was attributable to apoptotic cell death, as evidenced by mitochondrial cytochrome c release and DNA fragmentation in PC-3 cells (Fig. 2C) .
The relative potency paralleled that of troglitazone and D2-TG (Fig. 3A) . In contrast, rosiglitazone, pioglitazone, and their D2 counterparts showed marginal effects, even at 50 Amol/L, on apoptotic death in PC-3 cells (Fig. 3B) .
Together, these data suggest that thiazolidenediones mediated apoptosis induction in prostate cancer cell systems irrespective of PPARg activation.
Apoptosis-Active Thiazolidenediones Are Inhibitors of BclxL and Bcl-2 Functions. Our mechanistic study indicated that troglitazone and D2-TG were able to sensitize PC-3 cells to the apoptosis-inducing effect of the phosphoinositide 3-kinase inhibitor LY294002. 1 This finding, together with our recent report that attributed the resistance of PC-3 cells to LY294002-induced apoptosis to Bcl-xL overexpression (16) , suggests a plausible link between thiazolidenedione-induced apoptosis and modulation of the functions of Bcl-xL and/or other Bcl-2 members.
Accordingly, we examined this putative link by two distinct approaches at both transcriptional and posttranslational levels. First, we assessed the time-dependent effect of troglitazone (30 Amol/L) on the expression of different Bcl-2 family members Figure 3 . Differential effects of ciglitazone, rosiglitazone, pioglitazone, and their D2 derivatives on apoptotic death in PC-3 cells. A, dose-dependent effects of ciglitazone and D2-CG on PC-3 cell viability (left) and mitochondrial cytochrome c release (right ). Points, mean; bars, SD (n = 3). Cytochrome c release levels are normalized to h-actin levels (*P < 0.01). B , dose-dependent effects of rosiglitazone and D2-RG (left ), and pioglitazone and D2-PG (right ) on PC-3 cell viability. PC-3 cells were exposed to individual test agents at the indicated concentrations in serum-free RPMI 1640 in 96-well plates for 24 hours, and cell viability was assessed by MTT assay. Points, mean; bars, SD (n = 6). For the analysis of cytochrome c release, PC-3 cells were treated with the test agent at the indicated concentration for 24 hours in serum-free RMPI 1640 medium for 24 hours and mitochondria-free lysates were prepared. Equivalent amounts of protein from individual lysates were electrophoresed and probed by Western blotting with anti-cytochrome c antibody. 1 Unpublished data. Figure 2 . Evidence that the effect of troglitazone on apoptosis in prostate cancer cells is dissociated from PPARg activation. A, relative PPARg levels in PC-3 and LNCaP cells, normalized to a-tubulin levels. Columns, mean; bars, SD (n = 3). Inset , Western blot analysis of the expression status of PPARg (top ) and a-tubulin (bottom ) in PC-3 and LNCaP cells. *P < 0.01. B, dose-dependent effects of troglitazone and D2-TG on the cell viability of PC-3 and LNCaP cells. PC-3 cells were exposed to troglitazone or D2-TG at the indicated concentrations in serum-free RPMI 1640 in 96-well plates for 24 hours and cell viability was assessed by MTT assay. Points, mean; bars, SD (n = 6). C, evidence of apoptotic death in drug-treated PC-3 cells. Left , levels of cytochrome c release into cytoplasm induced by different doses of troglitazone and D2-TG. Columns, mean, normalized to h-actin levels; bars, SD (n = 3, *P < 0.01). PC-3 cells were treated with either agent at the indicated concentration for 24 hours in serum-free RMPI 1640 medium for 24 hours and mitochondria-free lysates were prepared. Equivalent amounts of protein from individual lysates were electrophoresed and probed by Western blotting with anti-cytochrome c antibody (inset ; h-actin blots are not shown). Right , formation of nucleosomal DNA in PC-3 cells that were treated with troglitazone or D2-TG at the indicated concentrations for 24 hours. DNA fragmentation was quantitatively measured by a cell death detection ELISA kit. Columns, mean; bars, SD (n = 3).
in PC-3 cells, including Bcl-xL, Bcl-2, Bax, Bak, Bad, and Bid. This analysis was based on recent reports that treatment of MCF-7 breast cancer and HepG2 hepatoma cells with high doses of troglitazone altered the expression levels of certain Bcl-2 members (9, 14) . Second, in light of the recent discovery of small-molecule Bcl-2 or Bcl-xL inhibitors that disrupt BH3 domain-mediated interactions with proapoptotic Bcl-2 members (20-26), we investigated the in vitro effects of thiazolidenediones and their D2 counterparts on the anti-apoptotic function of Bcl-xL and Bcl-2. It is well understood that the ability of Bcl-xL and Bcl-2 to form heterodimers with proapoptotic Bcl-2 members, via BH3 domain binding, plays a key role in their anti-apoptotic functions. Therefore, a well-established competitive fluorescence polarization analysis was used to examine the effects of thiazolidenediones on the binding of a Bak BH3 domain peptide to Bcl-xL and Bcl-2. Figure 4 indicates that with the exception of a slight decrease in Bad expression at 24 hours, the exposure of PC-3 cells to 30 Amol/L troglitazone did not cause appreciable change in the expression level of any of these Bcl-2 members throughout the course of investigation.
Nevertheless, data from the competitive fluorescence polarization analysis suggest that troglitazone, ciglitazone, and their D2 counterparts inhibited the anti-apoptotic functions of Bcl-xL and Bcl-2 by disrupting the BH3 domain-mediated interactions with proapoptotic Bcl-2 members. Figure 5A depicts the ability of troglitazone and D2-TG to displace the binding of a fluoresceinlabeled Bak BH3 domain peptide to Bcl-xL and Bcl-2. It is noteworthy that both compounds inhibited the BH3 peptide binding to Bcl-xL and Bcl-2 with equal potency, a distinct difference from many reported small-molecule inhibitors that showed discriminative affinity between these two anti-apoptotic Bcl-2 members. The IC 50 values for the inhibition of Bak BH3 peptide binding to either Bcl-xL or Bcl-2 were 22 F 1 and 18 F 1 Amol/L for troglitazone and D2-TG, respectively (Fig. 5A ). Ciglitazone and D2-CG showed similar effects on the proteinprotein interactions with comparable IC 50 values (Fig. 5B) . On the other hand, rosiglitazone, D2-RG, pioglitazone, and D2-PG, which were ineffective in inducing apoptotic death even at high doses, showed poor inhibitory activities with IC 50 significantly greater than 50 Amol/L. In light of the integral role of Bcl-2 members in the modulation of mitochondrial integrity, these in vitro binding data suggest that interference of the ability of Bcl-2 and Bcl-xL to bind with their proapoptotic Bcl-2 partners represented a major pathway for troglitazone, D2-TG, and ciglitazone counterparts to exert their apoptotic action. To corroborate this premise, we obtained two lines of evidence: (a) troglitazone and D2-TG attenuated the binding of intracellular Bcl-2 and Bcl-xL to proapoptotic Bcl-2 members and (b) overexpression of Bcl-xL provided protection against the drug-induced apoptosis.
Effect of Troglitazone and D2-TG on Intracellular Bcl-2 and Bcl-xL Binding to Bak. The functional relationship among different types of Bcl-2 family members in regulating the apoptosis machinery has been the focus of many recent investigations (27) . One school of thought is that Bcl-2 and Bcl-xL sequester Bax, Bak, and other proapoptotic Bcl-2 members through BH3 domainmediated heterodimerization, thereby abrogating their proapoptotic effects (28) (29) (30) (31) (32) . For example, electrophoretic introduction of Bak or Bax BH3 domain peptides into PC-3 cells disrupted Bcl-2-Bak heterodimer formation, which resulted in the liberation of Bax and Bak to mediate apoptotic death via a caspase-dependent pathway (32) . Consequently, to validate the mode of action of troglitazone and D2-TG, we assessed the effects on the dynamics of Bcl-2/Bak and Bcl-xL/Bak interactions in PC-3 cells. Lysates from PC-3 cells treated with troglitazone or D2-TG (50 Amol/L) vis-à-vis DMSO for 12 hours were immunoprecipitated with antibodies against Bcl-2 or Bcl-xL. Probing of the immunoprecipitates with anti-Bak antibodies by Western blotting indicates that the level of Bak associated with Bcl-2 and Bcl-xL was significantly reduced compared with the DMSO control ( Fig. 6A ; P < 0.01). This decrease in intracellular associations bore out the in vitro binding data that troglitazone and D2-TG inhibited the interactions of Bcl-xL and Bcl-2 with the Bak BH3-domain peptide. We further showed that treatment of PC-3 cells with troglitazone or D2-TG led to caspase-9 activation in a dose-dependent manner (Fig. 6B ) similar to that of cytochrome c release ( Fig. 2A) . Furthermore, pretreatment of PC-3 cells with the pan-caspase inhibitor Z-VAD-FMK protected cells from troglitazone-and D2-TG-induced apoptosis (P < 0.01; Fig. 6C ), confirming the involvement of caspase activation in apoptotic death.
Bcl-xL Overexpression Protects Prostate Cancer Cells from Troglitazone-and D2-TG-Induced Apoptosis. We previously reported that LNCaP cells exhibited lower Bcl-xL expression levels compared with PC-3 cells (16) , which underscored differences between these two cell lines in the susceptibility to the apoptotic effects of troglitazone, ciglitazone, and their D2 counterparts. To confirm that the inhibition of Bcl-xL functions plays a key role in the apoptosis induction, we examined the impact of Bcl-xL overexpression on the susceptibility to troglitazone-and D2-TGinduced cell death in LNCaP cells. Three transfected clones (B11, B1, and B3) that displayed ascending expression levels of Bcl-xL were tested vis-à-vis parental LNCaP cells (Fig. 7A) . Figure 7B depicts the differential protective effects of ectopic Bcl-xL on troglitazone-and D2-TG-induced apoptotic death among the three Bcl-xL clones, in which the extent of cytoprotection correlated with the Bcl-xL expression levels. Overexpression of ectopic Bcl-xL Figure 6 . Troglitazone and D2-TG trigger caspase-dependent apoptotic death by inhibiting heterodimer formation of Bcl-2 and Bcl-xL with Bak. A, effect of troglitazone and D2-TG on the dynamics of Bcl-2/Bak (left ) and Bcl-xL/Bak (right ) interactions in PC-3 cells. PC-3 cells were treated with 50 Amol/L troglitazone or D2-TG for 12 hours, and cell lysates were immunoprecipitated with anti-Bcl-2 or anti-Bcl-xL antibodies. The immunoprecipitates were probed with anti-Bak antibodies by Western blot analysis (WB ) as described in Materials and Methods. Columns, mean of the relative Bak levels, normalized to IgG light chains levels, in the three treatments; bars, SD (n = 3, *P < 0.01). B , dose-dependent effect of troglitazone and D2-TG on caspase-9 activation in PC-3 cells. PC-3 cells were treated with troglitazone or D2-TG at the indicated concentrations for 24 hours. Caspase-9 antibodies recognize the large subunits (35 and 37 kDa). C, protection of troglitazone and D2-TG-induced apoptosis in PC-3 cells by the pan-caspase inhibitor Z-VAD-FMK. PC-3 cells were pretreated with 100 Amol/L Z-VAD-FMK 12 hours before exposure to 30 Amol/L troglitazone or D2-TG in serum-free RPMI 1640 in 96-well plates for 24 hours, and cell viability was assessed by MTT assay. Columns, mean; bars, SD (n = 6, *P < 0.01).
conferred partial protection to the cytotoxic effects of troglitazone and D2-TG in B11 and B1 cells (P < 0.01), whereas the excessive expression in B3 cells completely overcame the inhibitory effect of troglitazone and D2-TG on Bcl-xL functions (P < 0.01). This protective effect was correlated with the inhibition of troglitazoneand D2-TG-induced cytochrome c release (P < 0.01; Fig. 7C ).
Development of Potent D2-TG-Derived Bcl-xL/Bcl-2 Binding Inhibitors. Troglitazone has previously been shown to be effective in suppressing PC-3 xenograft tumor growth at 500 mg/kg/d (33) . Dissociation of the effect of troglitazone on apoptosis from PPARg activation provided a molecular rationale to structurally optimize D2-TG to develop potent Bcl-xL/Bcl-2 binding inhibitors. Accordingly, we synthesized a series of D2-TG derivatives and their activities in inhibiting BH3 domain-mediated Bcl-xL-Bak peptide binding were examined.
2 Among >30 derivatives examined, TG-88 represented an optimal agent with an order-of-magnitude higher potency than D2-TG in fluorescence polarization-based Bcl-xL binding inhibition (IC 50 , 1.8 F 0.2 Amol/L) and PC-3 cell proliferation (IC 50 , 2.5 F 0.2 Amol/L). In addition, like D2-TG, TG-88 lacked appreciable activity in PPARg activation. To examine its therapeutic relevance, we assessed the in vivo effect of daily p.o. TG-88 at two different doses, 100 and 200 mg/kg, on the growth of PC-3 xenograft tumors (Fig. 8) . All animals tolerated the treatments well without observable signs of toxicity and were characterized by stable body weights throughout the course of study. No gross pathologic abnormalities were noted at necropsy after 63 days of treatment. As shown, both treatments displayed a significant inhibitory effect (P < 0.05) when the tumors of control animals entered an exponential growth phase at day 35 and beyond. After 63 days of treatment, the extents of tumor growth inhibition were 50% and 61% for groups receiving 100 and 200 mg/kg/d, respectively.
Discussion
Although accumulating evidence suggests that troglitazone and ciglitazone mediate PPARg-independent antitumor effects, the underlying mechanism remains undefined. Here, we obtained several lines of evidence that the effects of these thiazolidenediones on apoptosis in prostate cancer cells were attributable in part to the inhibition of Bcl-xL/Bcl-2 functions independently of PPARg activation. First, D2-TG and D2-CG, although devoid of PPARg activity, exhibited slightly higher potency than troglitazone and ciglitazone, respectively, in inducing apoptotic death irrespective of differences in PPARg expression levels between LNCaP and PC-3 cells. In contrast, rosiglitazone and pioglitazone, two thiazolidenediones currently in clinical use for the treatment of diabetes, lacked appreciable effects on apoptosis despite their higher potency in PPARg activation than troglitazone and ciglitazone. Second, a correlation exists between the potency in inhibiting BH3 peptide binding to Bcl-xL or Bcl-2 and the effectiveness in inducing apoptosis in prostate cancer cells. For example, the inability of 5 PC-3 cells suspended in 0.1 mL serum-free medium containing 30% Matrigel under isoflurane anesthesia. Forty-eight hours later, mice were randomly divided into three groups (n = 8) and were given daily TG-88 at 100 and 200 mg/kg body weight per day by gavage for the duration of the study. Controls received vehicle consisting of 0.5% methylcellulose and 0.1% polysorbate 80 in sterile water. Points, mean; bars, SE (n = 8; *P < 0.05 compared with the control group).
2 Chen, in preparation. Figure 7 . Ectopic Bcl-xL protects LNCaP cells from troglitazone-and D2-TG-induced apoptosis by attenuating cytochrome c release in an expression level-dependent manner. A, left, ascending expression levels of ectopic Bcl-xL in B11, B1, and B3 clones. Columns, mean; bars, SD (n =3, *P < 0.01). Right, Western blot analysis. The band for ectopic Bcl-xL contained a FLAG tag (eight amino acids long) from the construct, thus migrating slower than endogenous Bcl-xL. B, dose-dependent effects of troglitazone (left ) and D2-TG (right ) on apoptosis in LNCaP, B11, B1, and B3 cells. Points, mean; bars, SD (n = 3). C, ectopic expression of Bcl-xL inhibits the effect of troglitazone (50 Amol/L) and D2-TG (50 Amol/L) on cytochrome c release. Cells were treated with DMSO vehicle (À) or with 50 Amol/L troglitazone or D2-TG (+) Cytosol-specific, mitochondria-free lysates were prepared. Equivalent amounts of protein from individual lysates were electrophoresed and probed by Western blotting with anti-cytochrome c antibody. The relative ratios of cytoplasmic cytochrome c in drug-treated to vehicle-treated cells are shown below the Western blots. Values, means F SD (n = 3).
rosiglitazone and pioglitazone to trigger apoptotic death was reflected in their weak potency in displacing BH3 domainmediated interactions. It is interesting that introduction of a double bond adjoining the terminal thiazolidine-2,4-dione ring in troglitazone and ciglitazone enhanced the Bcl-xL/Bcl-2 inhibitory activity, while abrogating the ability to activate PPARg. Presumably, this change in pharmacologic profiles was attributable to the structural rigidity surrounding the heterocyclic system as a result of the double-bond introduction. Third, the immunoprecipitation study indicates that the level of Bak associated with Bcl-2 and Bcl-xL was greatly reduced in troglitazone-and D2-TG-treated cells compared with DMSO control. Disruption of the BH3 domainmediated interactions led to the liberation of proapoptotic Bcl-2 members, which caused cells to undergo apoptosis by facilitating cytochrome c release and caspase-9 activation. This premise was borne out by the ability of Z-VAD-FMK to protect cells from troglitazone-and D2-TG-induced apoptosis. Fourth, overexpression of Bcl-xL provided LNCaP cells protection against troglitazone-and D2-TG-induced apoptosis.
Considering the pivotal role of Bcl-xL and Bcl-2 in regulating mitochondrial integrity, this new mode of action provides a molecular framework to account for the PPARg-independent effects of thiazolidenediones on apoptotic death in cancer cells. It is also noteworthy that troglitazone, ciglitazone, and their D2 derivatives lack specificity in recognizing Bcl-xL and Bcl-2. This relaxed specificity might prove advantageous in light of the importance of both Bcl-2 members in regulating apoptosis thresholds to chemotherapeutic agents.
In summary, the impetus of the dissociation of the in vitro antitumor activities of thiazolidenediones from PPARg activation is multifold. First, although troglitazone has been shown to reduce the growth of xenograft tumors in nude mice (33, 34) , this PPARg agonist has also been reported to promote the development of colon tumors and enhance colon polyp formation in APC Min mice that are genetically predisposed to intestinal neoplasia (35, 36) . Thus, a crucial issue that warrants investigation is the role of PPARg activation in tumorigenic promotion vis-à-vis antitumor effects in these animal model studies. Conceivably, thiazolidenediones and their PPARg-inactive D2 derivatives provide useful tools to shed light onto the link between PPARg activation and increased cancer risk. Second, from a translational perspective, separation of these two pharmacologic activities provides molecular underpinnings to use thiazolidenediones, especially D2-TG and D2-CG, as molecular platforms to design Bcl-xL/Bcl-2 inhibitors with greater in vitro and in vivo antitumor potency. Third, owing to the heterogeneous nature of prostate cancer, different prostate tumor cell lines display differential sensitivity to various apoptotic signals. For example, PC-3 cells are able to resist apoptotic signals emanating from withdrawal of trophic factors, and exposure to cytokines and chemotherapeutic agents, in part owing to elevated levels of Akt activation and BclxL overexpression. Consequently, these molecules have translational relevance to be developed into antitumor agents for the prevention and/or therapy of cancers alone or in combination with other treatments. The proof of principle for this premise was TG-88, a close structural analogue of D2-TG, with an order-ofmagnitude higher potency than D2-TG in blocking Bcl-xL binding and inhibiting PC-3 cell proliferation. Oral TG-88 at 100 and 200 mg/kg/d was effective in suppressing PC-3 xenograft tumor growth without causing weight loss or apparent toxicity, indicating its p.o. bioavailability and potential clinical use. Further development of these novel agents for the prevention and/or treatment of prostate cancer is currently under way.
